Recruiting

Extracellular Vesicles

Sponsor:

University of Minnesota

Code:

NCT05843552

Conditions

Gaucher Disease

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

no intervention

Study Details

Brief summary:

This is an observational study intended to generate preliminary data to understand how lysosomal dysfunction can affect the biogenesis of extracellular vesicles, its content and function. The primary objective of the proposed project is to decipher how extracellular vesicle (EV) biogenesis and its role in intercellular communication can be impaired as a consequence of defects in lysosomal function. Collectively these defects in EV biogenesis and function can contribute to the neuroinflammation observed in lysosomal storage diseases. Since EVs can cross the blood-brain barrier, their characterization may be valuable in identifying novel biomarkers. In the presence of a GBA1 mutation, the decrease in GCase activity will lower overall lysosome function and increase the secretion of EVs. Further, there will be differences in EV size, its cargo including lipids, RNA and proteins and their aggregates. In comparison to healthy controls, EVs isolated from patients with Gaucher disease (GD) and GBA1 carriers is hypothesized to show significant differences in terms of its characteristics and content, which can contribute to our understanding of the link between lysosomes and neurological disease.

Conditions

Gaucher Disease

Study ID

NCT05843552

Start date

Aug 14, 2023

Status verified date

Apr, 2026

Completion date

Dec 31, 2026

Anticipated

Primary completion date

Dec 31, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Age between 18-80yrs
  • Restricted to participants who are untreated, obligate carriers and healthy controls.
  • Participants with GD should have confirmed GD diagnosis, mutation confirmed for carriers and healthy controls confirmed to have no GBA1 mutation by gene sequencing.

Exclusion Criteria:

  • Exclude participants who have any hematological malignancy or other uncontrolled comorbid conditions.
  • Exclude participants who are currently on therapy for their GD
  • Exclude participants who have any hematological malignancy or other uncontrolled comorbid conditions.

Study Design

Enrollment

30 participants

Anticipated

Interventions and Outcome Measures

Arms

patients with GD

obligate carriers

healthy volunteers

Interventions

no intervention

no intervention, this is an observational study

Primary outcome measure

  • EVs quantity [ Time Frame: baseline ]
  • EVs quantity [ Time Frame: 3months ]
  • EVs size [ Time Frame: baseline ]
  • EVs size [ Time Frame: 3months ]
  • EVs content [ Time Frame: baseline ]
  • EVs content [ Time Frame: 3months ]

Central Contacts and Locations

Central contacts

Reena Kartha, PhD, MS

612-626-2436rvkartha@umn.edu

Locations

University of Minnesota

Recruiting

Minneapolis, Minnesota, United States, 55414

Contacts

Reena Kartha, PhD, MS

612-626-2436rvkartha@umn.edu

More Information

Sponsor

University of Minnesota

Last update posted

Apr 6, 2026

Last verified

Apr, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of Minnesota on 2026-04-06.